BeiGene Ltd ( (HK:6160) ) has provided an announcement.
BeiGene, Ltd. has issued an overseas regulatory announcement regarding the filing of its amended annual report, Form 10-K/A, with the U.S. Securities and Exchange Commission. This filing is significant as it reflects the company’s compliance with regulatory requirements and provides updated financial and operational information, which is crucial for stakeholders and investors to assess the company’s current market position and future prospects.
More about BeiGene Ltd
BeiGene, Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative cancer therapies. The company is listed on The Stock Exchange of Hong Kong Limited and the Nasdaq Global Select Market, with a market presence in the United States and China.
YTD Price Performance: 52.66%
Average Trading Volume: 2,473,919
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$241.4B
See more data about 6160 stock on TipRanks’ Stock Analysis page.